• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception.19至24岁年轻女性在4至5年单纯使用和混合使用激素避孕方法后的骨矿物质密度。
Contraception. 2009 Aug;80(2):128-32. doi: 10.1016/j.contraception.2009.02.001. Epub 2009 Mar 19.
2
Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception.使用庚酸炔诺酮、醋酸甲羟孕酮长效注射剂或复方口服避孕药避孕的青少年的骨矿物质密度
Contraception. 2007 Jun;75(6):438-43. doi: 10.1016/j.contraception.2007.02.001. Epub 2007 Apr 5.
3
Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.40至49岁使用醋酸甲羟孕酮长效注射剂、庚酸炔诺酮或复方口服避孕药进行避孕的女性的骨矿物质密度。
Contraception. 2005 Mar;71(3):170-5. doi: 10.1016/j.contraception.2004.09.003.
4
Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate.在一组青少年使用庚酸炔诺酮、醋酸甲羟孕酮长效注射剂或复方口服避孕药期间以及停用庚酸炔诺酮后的骨矿物质密度。
Contraception. 2009 May;79(5):345-9. doi: 10.1016/j.contraception.2008.11.009. Epub 2009 Jan 17.
5
Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception.新青春期使用 DMPA、NET-EN、COC、未使用者和激素避孕中断者体重变化的前瞻性研究。
Contraception. 2010 Jan;81(1):30-4. doi: 10.1016/j.contraception.2009.07.007.
6
Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception.使用醋酸甲羟孕酮、庚酸炔诺酮或复方口服避孕药评估 40-49 岁女性的绝经状态。
S Afr Med J. 2011 Feb;101(2):131-5. doi: 10.7196/samj.4224.
7
Pharmacodynamic effects of once-a-month combined injectable contraceptives.每月一次复方注射用避孕药的药效学效应。
Contraception. 1994 Apr;49(4):361-85. doi: 10.1016/0010-7824(94)90033-7.
8
Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study.使用注射用或口服避孕药的青春期女性的骨矿物质密度:一项为期24个月的前瞻性研究。
Fertil Steril. 2008 Dec;90(6):2060-7. doi: 10.1016/j.fertnstert.2007.10.070. Epub 2008 Jan 28.
9
Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception.接受复方口服避孕药和醋酸甲羟孕酮长效避孕针避孕的女性不同解剖学骨部位的骨矿物质密度。
Contraception. 2002 Jun;65(6):407-10. doi: 10.1016/s0010-7824(02)00308-6.
10
A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.长期使用注射用长效醋酸甲羟孕酮避孕者前臂骨密度的横断面研究。
Contraception. 2011 Nov;84(5):e31-7. doi: 10.1016/j.contraception.2011.06.012. Epub 2011 Aug 10.

引用本文的文献

1
Carbohydrate, lipid, bone and inflammatory markers in HIV-positive adolescents on antiretroviral therapy and hormonal contraception.接受抗逆转录病毒治疗和激素避孕的HIV阳性青少年的碳水化合物、脂质、骨和炎症标志物
J Virus Erad. 2017 Jan 1;3(1):56-60. doi: 10.1016/S2055-6640(20)30297-1.
2
Contraception for HIV-Infected Adolescents.感染艾滋病毒青少年的避孕措施
Pediatrics. 2016 Sep;138(3). doi: 10.1542/peds.2016-1892.
3
Contraceptive challenges in adolescents living with or at risk of HIV.青少年在感染或面临 HIV 风险下的避孕挑战。
J Virus Erad. 2016 Apr 1;2(2):82-6. doi: 10.1016/S2055-6640(20)30474-X.
4
Contraception in HIV-positive female adolescents.HIV 阳性的青春期少女避孕。
AIDS Res Ther. 2011 Jun 1;8(1):19. doi: 10.1186/1742-6405-8-19.
5
Oral contraceptive use and bone.口服避孕药与骨骼。
Curr Osteoporos Rep. 2011 Mar;9(1):6-11. doi: 10.1007/s11914-010-0037-9.

本文引用的文献

1
Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate.在一组青少年使用庚酸炔诺酮、醋酸甲羟孕酮长效注射剂或复方口服避孕药期间以及停用庚酸炔诺酮后的骨矿物质密度。
Contraception. 2009 May;79(5):345-9. doi: 10.1016/j.contraception.2008.11.009. Epub 2009 Jan 17.
2
Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density.醋酸甲羟孕酮长效注射剂和20微克口服避孕药对骨密度的影响。
Obstet Gynecol. 2008 Oct;112(4):788-99. doi: 10.1097/AOG.0b013e3181875b78.
3
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.使用醋酸甲羟孕酮长效注射避孕针后骨密度的恢复情况。
Contraception. 2008 Feb;77(2):67-76. doi: 10.1016/j.contraception.2007.10.005.
4
Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study.使用注射用或口服避孕药的青春期女性的骨矿物质密度:一项为期24个月的前瞻性研究。
Fertil Steril. 2008 Dec;90(6):2060-7. doi: 10.1016/j.fertnstert.2007.10.070. Epub 2008 Jan 28.
5
Bone status after cessation of use of injectable progestin contraceptives.停用注射用孕激素避孕药后的骨状况。
Contraception. 2007 Dec;76(6):425-31. doi: 10.1016/j.contraception.2007.08.010. Epub 2007 Nov 9.
6
Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception.使用庚酸炔诺酮、醋酸甲羟孕酮长效注射剂或复方口服避孕药避孕的青少年的骨矿物质密度
Contraception. 2007 Jun;75(6):438-43. doi: 10.1016/j.contraception.2007.02.001. Epub 2007 Apr 5.
7
Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate.首次使用醋酸甲羟孕酮长效注射剂的48个月期间骨矿物质密度的丢失与恢复情况。
Fertil Steril. 2006 Nov;86(5):1466-74. doi: 10.1016/j.fertnstert.2006.05.024. Epub 2006 Sep 25.
8
Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women.口服避孕药对248名年轻女性队列中骨量和骨几何参数的有害影响。
Bone. 2007 Feb;40(2):444-50. doi: 10.1016/j.bone.2006.08.001. Epub 2006 Sep 11.
9
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.接受醋酸甲羟孕酮长效注射剂的25至35岁女性的骨矿物质密度:停药后的恢复情况。
Contraception. 2006 Aug;74(2):90-9. doi: 10.1016/j.contraception.2006.03.010. Epub 2006 May 19.
10
Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.醋酸甲羟孕酮长效注射剂与青少年骨密度——黑框警告:青少年医学协会立场文件
J Adolesc Health. 2006 Aug;39(2):296-301. doi: 10.1016/j.jadohealth.2006.03.011.

19至24岁年轻女性在4至5年单纯使用和混合使用激素避孕方法后的骨矿物质密度。

Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception.

作者信息

Beksinska Mags E, Kleinschmidt Immo, Smit Jenni A, Farley Timothy M M, Rees Helen V

机构信息

Reproductive Health and HIV Research Unit, Department of Obstetrics and Gynaecology, University of the Witwatersrand, Mayville, 4091, South Africa.

出版信息

Contraception. 2009 Aug;80(2):128-32. doi: 10.1016/j.contraception.2009.02.001. Epub 2009 Mar 19.

DOI:10.1016/j.contraception.2009.02.001
PMID:19631787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3819654/
Abstract

BACKGROUND

Use of depot-medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN) and low-dose combined oral contraceptives (COCs) has been associated with loss of bone mineral density (BMD) in adolescents. However, the effect of using a combination of these methods over time in this age group is limited. The aim of this cross-sectional study was to investigate BMD in young women (aged 19-24 years) with a history of mixed hormonal contraceptive use.

STUDY DESIGN

BMD was measured at the spine, hip and femoral neck using dual X-ray absorptiometry. Women were classified into three groups: (1) injectable users (DMPA, NET-EN or both) (n=40), (2) mixed COC and injectable users (n=13) and (3) non-user control (n=41).

RESULTS

Women in the injectables-only user group were found to have lower BMDs compared to the non-user group at all three sites, and there was evidence of a difference in BMD between these two groups at the spine after adjusting for body mass index (p=.042), hip (p=.025) and femoral neck (p=.023). The mixed COC/injectable user group BMD values were lower than those for controls; however, there was no evidence of a significant difference between this group and the non-user group at any of the three sites.

CONCLUSION

This study suggests that BMD is lower in long-term injectable users but not when women have mixed injectable and COC use.

摘要

背景

使用醋酸甲羟孕酮长效注射剂(DMPA)、庚酸炔诺酮(NET-EN)和低剂量复方口服避孕药(COC)与青少年骨矿物质密度(BMD)的降低有关。然而,在这个年龄组中,随着时间的推移联合使用这些方法的效果有限。这项横断面研究的目的是调查有混合激素避孕使用史的年轻女性(19 - 24岁)的骨矿物质密度。

研究设计

使用双能X线吸收法测量脊柱、髋部和股骨颈的骨矿物质密度。女性被分为三组:(1)注射剂使用者(DMPA、NET-EN或两者皆用)(n = 40),(2)复方口服避孕药和注射剂混合使用者(n = 13),以及(3)非使用者对照组(n = 41)。

结果

仅使用注射剂的使用者组在所有三个部位的骨矿物质密度均低于非使用者组,并且在调整体重指数后,这两组在脊柱(p = 0.042)、髋部(p = 0.025)和股骨颈(p = 0.023)的骨矿物质密度存在差异。复方口服避孕药/注射剂混合使用者组的骨矿物质密度值低于对照组;然而,在这三个部位中的任何一个部位,该组与非使用者组之间均无显著差异的证据。

结论

这项研究表明,长期注射剂使用者的骨矿物质密度较低,但在女性同时使用注射剂和复方口服避孕药时并非如此。